rare blood diseases

View All

Hemophilia A Market Forecast and Assessment
Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape

Hemophilia A treatment scenario before the launch of HEMLIBRA Despite the ups and downs throughout history, the management of hemophilia A patients substantially improved over the past 40 years. The groundbreaking discovery of cryoprecipitate in 1964 marked the beginning of the modern progression of hemophilia t...

Find More

Hypofibrinogenemia Market | Rare Bleeding Disorders
Hypofibrinogenemia Market: Limited Pipeline Therapies, Abundant Opportunities

Like troops at the forefront of any battle, our immune system continually marches to protect us from foreign elements and invaders, including bacteria, viruses, and others. Whenever with a swift wave of wind, something falls in our eyes, our immune system produces tears to get rid of the invader. Or at times when w...

Find More

BioGen
Business Cocktail

M&A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & blood disorders-focused company for USD 105 per share on March 8, 2018. This will increase Sanofi’s hemophilia portfolio for...

Find More